ERBB2 and breast carcinoma: In detail, 16.8% (n = 16) patients showed a conversion from HER2-0 primary breast cancer to HER2-low-positive residual disease, 21.1% showed a switch in the opposite direction (n = 20) and 1.1% (n = 1) exhibited the acquisition of HER2-positive status.